trending Market Intelligence /marketintelligence/en/news-insights/trending/cotz6x5kmufez5ftabq7fw2 content esgSubNav
In This List

Northwest Biotherapeutics raises $1.1M via securities offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Northwest Biotherapeutics raises $1.1M via securities offering

Northwest Biotherapeutics, Inc. said it made additional sales of its series B preferred stock and class D-2 warrants to certain investors from May 4 to May 17.

The Bethesda, Md.-based biotechnology company issued 487,117 series B preferred stock at $2.30 apiece for about $1.1 million.

Each share of series B preferred stock is convertible into 10 common shares.

The company also issued class D-2 warrants to acquire up to 4,871,170 common shares at an exercise price of 30 cents per share.

Northwest said that since May 4, about 111,765 series A preferred stock and 271,955 series B preferred stock were converted into 3,837,200 common shares.